Carcinoma of the Head and Neck Clinical Trial
Official title:
Open-label, Non-randomized, Non-controlled, Multicenter Phase II Study Investigating Cetuximab in Combination With Concomitant-boost Radiotherapy as First-line Treatment for Japanese Patients With Newly Diagnosed Locally Advanced SCCHN.
This study is conducted in Japanese newly diagnosed locally advanced SCCHN patients in order to assess tolerability and feasibility of Cetuximab plus concomitant boost radiotherapy (RT) regimen (the study treatment) and its safety profile (i.e. AEs: adverse events). In addition, efficacy (i.e. anti-tumor effect) of the study treatment is also evaluated.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00184028 -
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Withdrawn |
NCT00257335 -
Intensity-Modulated Radiotherapy for Recurrent Head and Neck Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Completed |
NCT03733210 -
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
|
Phase 1 | |
| Recruiting |
NCT03001570 -
Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District
|
Phase 2 | |
| Completed |
NCT02626000 -
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)
|
Phase 1 | |
| Completed |
NCT00050388 -
Phase II Trial of Allovectin-7® for Head and Neck Cancer
|
Phase 3 |